Results 151 to 160 of about 22,932 (328)

A Core Head, Neck, and Neuroanatomy Syllabus for Physical Therapy Student Education

open access: yesClinical Anatomy, EarlyView.
ABSTRACT Head, neck, and neuroanatomy are essential components of physical therapy education due to their broad clinical applications. Detailed syllabi exist for medical students, yet none have been developed for physical therapy. This study aimed to produce an International Federation of Associations of Anatomists core head, neck, and neuroanatomy ...
Stephanie J. Woodley   +4 more
wiley   +1 more source

PLK4: Master Regulator of Centriole Duplication and Its Therapeutic Potential

open access: yesCytoskeleton, EarlyView.
ABSTRACT Centrosomes catalyze the assembly of a microtubule‐based bipolar spindle, essential for the precise chromosome segregation during cell division. At the center of this process lies Polo‐Like Kinase 4 (PLK4), the master regulator that controls the duplication of the centriolar core to ensure the correct balance of two centrosomes per dividing ...
Muhammad Hamzah   +2 more
wiley   +1 more source

Deglutition manifestations in patients with oropharyngeal cancer subjected to conservative therapy: systematic review

open access: diamond, 2020
Jucimara N. Gois   +4 more
openalex   +1 more source

Pharmacokinetics and Bioequivalence of a Novel Extended‐Release Formulation of Methylphenidate Hydrochloride for Attention‐Deficit/Hyperactivity Disorder

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Extended‐release (ER) formulations of the stimulant methylphenidate are commonly used to treat attention‐deficit/hyperactivity disorder in both children and adults. Previous studies have shown that the clinical effectiveness of long‐acting methylphenidate formulations is closely tied to the drug's pharmacokinetic (PK) profile, highlighting the
Ann C. Childress   +2 more
wiley   +1 more source

Artificial intelligence in the diagnosis and management of dysphagia: a scoping review. [PDF]

open access: yesCodas
Silva RDD   +8 more
europepmc   +1 more source

Relative Bioavailability, Food Effect, and Bioequivalence Studies to Assess a New Zanubrutinib 160‐mg Tablet: Results From 2 Phase 1 Studies in Healthy Volunteers

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Zanubrutinib is a next‐generation Bruton tyrosine kinase inhibitor approved for treating B‐cell malignancies. Two phase 1 studies evaluated a new 160‐mg zanubrutinib tablet versus 80‐mg capsules. In study BGB‐3111‐115 (n = 43), a randomized 3‐period crossover trial, relative bioavailability and food effects were assessed.
Bilal Tariq   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy